Novel combination for the treatment of airway disorders

• US 20050222193A1
• Filed: 05/03/2003
• Published: 10/06/2005
• Est. Priority Date: 05/07/2002
• Status: Abandoned Application

• Current Assignee: Altana Pharma AG (Takeda Pharmaceutical Company Limited)
• Original Assignee: Altana Pharma AG (Takeda Pharmaceutical Company Limited)
• Inventors: Hanauer, Guido, Kromer, Wolfgang, Simon, Wolfgang-Alexander, Postius, Stefan
• Application Number:
  US10/513,598
• Publication Number:
  US 20050222193A1
• Time in Patent Office: Days
• US Class Current: 514/292
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system

Abstract

The invention relates to the combination of reversible proton pump inhibitors and airway therapeutics for the treatment of airway disorders.

Claims

1. A pharmaceutical composition comprising a reversible proton pump inhibitor and an airway therapeutic in fixed or free combination.

2. A pharmaceutical composition according to claim 1 in fixed oral combination.

9. A pharmaceutical composition according to claim 1, wherein the reversible proton pump inhibitor is selected from the group consisting of AU-461, BY359, DBM-819, KR-60436, T-330, YH-1885, YJA-20379-8 and (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxy-ethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine and the hydrates, solvates, salts, hydrates of the salts and solvates of the salts thereof.

10. A pharmaceutical composition according to claim 1, wherein the airway therapeutic is selected from the group consisting of cis-[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexane-1-carboxylic acid (CILOMILAST), 2-methyl-1-[2-(1-methylethyl)pyrazolo-[1,5-a]pyridin-3-yl]-1-propanone (IBUDILAST), (−

)-cis-9-ethoxy-8-methoxy-2-methyl-1,2,3,4,4a,10b-hexahydro-6-(4-diisopropylaminocarbonylphenyl)benzo[c][1,6]naphthyridine (PUMAFENTRINE), 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridyl)-4-difluoromethoxy)benzamide (ROFLUMILAST), ROFLUMILAST N-OXIDE and the hydrates, solvates, salts, hydrates of the salts and solvates of the salts thereof.

11. A pharmaceutical composition according to claim 1, wherein the reversible proton pump inhibitor is selected from the group consisting of (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo-[1,2-h][1,7]naphthyridine (Soraprazan), (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7H-8,9-dihydro-pyrano[2,3-c]imidazo[1,2-a]pyridine, (7R,8R,9R)-7-(2-methoxyethoxy)-2,3-dimethyl-8-(N,N-dimethylaminomethylcarbonyloxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine, 7-(4-fluoro-benzyloxy)-2,3-dimethyl-1-(2-methyl-cyclopropylmethyl)-1H-pyrrolo[2,3-d]pyridazine, 7-(4-chloro-benzyloxy)-2,3-dimethyl-1-(2-methyl-cyclopropylmethyl)-1H-pyrrolo[2,3-d]pyridazine, 7-(2,4-difluoro-benzyloxy)-2,3-dimethyl-1-(2-methyl-cyclopropylmethyl)-1H-pyrrolo[2,3-d]pyridazine, 8-(2,6-dimethyl-benzylamino)-2,3-dimethyl-imidazo[1,2-a]pyridine-6-carboxylic acid (2-hydroxy-ethyl)-amide, 8-(2-ethyl-6-methyl-benzylamino)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxylic acid amide and the hydrates, solvates, salts, hydrates of the salts and solvates of the salts thereof.

12. A pharmaceutical composition according to claim 1, wherein the reversible proton pump inhibitor is selected from the group consisting of (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo-[1,2-h][1,7]naphthyridine (Soraprazan), (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7H-8,9-dihydro-pyrano[2,3-c]imidazo[1,2-a]pyridine, (7R,8R,9R)-7-(2-methoxyethoxy)-2,3-dimethyl-8-(N,N-dimethylaminomethylcarbonyloxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine and the hydrates, solvates, salts, hydrates of the salts and solvates of the salts thereof.

13. A pharmaceutical composition according to claim 1, wherein the reversible proton pump inhibitor is selected from the group consisting of (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo-[1,2-h][1,7]naphthyridine (Soraprazan), (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7H-8,9-dihydro-pyrano[2,3-c]imidazo[1,2-a]pyridine, (7R,8R,9R)-7-(2-methoxyethoxy)-2,3-dimethyl-8-(N,N-dimethylaminomethylcarbonyloxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h](1,7]naphthyridine and the hydrates, solvates, salts, hydrates of the salts and solvates of the salts thereof, and wherein the airway therapeutic is CICLESONIDE or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.

14. A pharmaceutical composition according to claim 1, wherein the reversible proton pump inhibitor is selected from the group consisting of (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo-[1,2-h][1,7]naphthyridine (Soraprazan), (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7H-8,9-dihydro-pyrano[2,3-c]imidazo[1,2-a]pyridine, (7R,8R,9R)-7-(2-methoxyethoxy)-2,3-dimethyl-8-(N,N-dimethylaminomethylcarbonyloxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine and the hydrates, solvates, salts, hydrates of the salts and solvates of the salts thereof, and wherein the airway therapeutic is 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridyl)-4-(difluoromethoxy)benzamide (ROFLUMILAST), ROFLUMILAST-N-OXIDE or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.

15. A pharmaceutical composition according to claim 1, wherein the reversible proton pump inhibitor is selected from the group consisting of (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo-[1,2-h][1,7]naphthyridine (Soraprazan) or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof, and wherein the airway therapeutic is 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridyl)-4-(difluoromethoxy)benzamide (ROFLUMILAST) or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.

16. A pharmaceutical composition according to claim 1, wherein the reversible proton pump inhibitor is selected from the group consisting of (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo-[1,2-h][1,7]naphthyridine (Soraprazan) or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof, and wherein the airway therapeutic is CICLESONIDE or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.

3. A method for treating an airway disorder in a patient comprising administering to a patient in need of such a treatment an effective amount of a reversible proton pump inhibitor together with an airway therapeutic.

4. A method according to claim 3, wherein the airway disorder is selected from the group consisting of bronchitis, obstructive bronchitis, COPD, spastic bronchitis, allergic bronchitis, allergic asthma, bronchial asthma, pneumonitis and pulmonary fibrosis.

17. A method according to claim 3, wherein the reversible proton pump inhibitor is selected from the group consisting of AU-461, BY359, DBM-819, KR-60436, T-330, YH-1885, YJA-20379-8 and (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxy-ethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine and the hydrates, solvates, salts, hydrates of the salts and solvates of the salts thereof.

18. A method according to claim 3, wherein the airway therapeutic is selected from the group consisting of cis-[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexane-1-carboxylic acid (CILOMILAST), 2-methyl-1-[2-(1-methylethyl)pyrazolo-[1,5-a]pyridin-3-yl]-1-propanone (IBUDILAST), (−

)-cis-9-ethoxy-8-methoxy-2-methyl-1,2,3,4,4a,10b-hexahydro-6-(4-diisopropylamino-carbonylphenyl)benzo[c][1,6]-naphthyridine (PUMAFENTRINE), 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridyl)-4-difluoromethoxy)benzamide (ROFLUMILAST), ROFLUMILAST N-OXIDE and the hydrates, solvates, salts, hydrates of the salts and solvates of the salts thereof.

19. A method according to claim 3, wherein the reversible proton pump inhibitor is selected from the group consisting of (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo-[1,2-h][1,7]naphthyridine (Soraprazan), (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7H-8,9-dihydro-pyrano[2,3-c]imidazo[1,2-a]pyridine, (7R,8R,9R)-7-(2-methoxyethoxy)-2,3-dimethyl-8-(N,N-dimethylaminomethylcarbonyloxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine, 7-(4-fluoro-benzyloxy)-2,3-dimethyl-1-(2-methyl-cyclopropylmethyl)-1H-pyrrolo[2,3-d]pyridazine, 7-(4-chloro-benzyloxy)-2,3-dimethyl-1-(2-methyl-cyclopropylmethyl)-1H-pyrrolo[2,3-d]pyridazine, 7-(2,4-difluoro-benzyloxy)-2,3-dimethyl-1-(2-methyl-cyclopropylmethyl)-1H-pyrrolo[2,3-d]pyridazine, 8-(2,6-dimethyl-benzylamino)-2,3-dimethyl-imidazo[1,2-a]pyridine-6-carboxylic acid (2-hydroxy-ethyl)-amide, 8-(2-ethyl-6-methyl-benzylamino)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxylic acid amide and the hydrates, solvates, salts, hydrates of the salts and solvates of the salts thereof.

20. A method according to claim 3, wherein the reversible proton pump inhibitor is selected from the group consisting of (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxy-ethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo-[1,2-h][1,7]naphthyridine (Soraprazan), (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7H-8,9-dihydro-pyrano[2,3-c]imidazo[1,2-a]pyridine, (7R,8R,9R)-7-(2-methoxyethoxy)-2,3-dimethyl-8-(N,N-dimethylaminomethylcarbonyloxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine and the hydrates, solvates, salts, hydrates of the salts and solvates of the salts thereof.

21. A method according to claim 3, wherein the reversible proton pump inhibitor is selected from the group consisting of (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxy-ethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo-[1,2-h][1,7]naphthyridine (Soraprazan), (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7H-8,9-dihydro-pyrano[2,3-c]imidazo[1,2-a]pyridine, (7R,8R,9R)-7-(2-methoxyethoxy)-2,3-dimethyl-8-(N,N-dimethylaminomethylcarbonyloxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine and the hydrates, solvates, salts, hydrates of the salts and solvates of the salts thereof, and wherein the airway therapeutic is CICLESONIDE or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.

22. A method according to claim 3, wherein the reversible proton pump inhibitor is selected from the group consisting of (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxy-ethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo-[1,2-h][1,7]naphthyridine (Soraprazan), (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7H-8,9-dihydro-pyrano[2,3-c]imidazo[1,2-a]pyridine, (7R,8R,9R)-7-(2-methoxyethoxy)-2,3-dimethyl-8-(N,N-dimethylaminomethylcarbonyloxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine and the hydrates, solvates, salts, hydrates of the salts and solvates of the salts thereof, and wherein the airway therapeutic is 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridyl)-4-(difluoromethoxy)benzamide (ROFLUMILAST), ROFLUMILAST-N-OXIDE or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.

23. A method according to claim 3, wherein the reversible proton pump inhibitor is selected from the group consisting of (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxy-ethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo-[1,2-h][1,7]naphthyridine (Soraprazan) or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof, and wherein the airway therapeutic is 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridyl)-4-(difluoromethoxy)benzamide (ROFLUMILAST) or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.

24. A method according to claim 3, wherein the reversible proton pump inhibitor is selected from the group consisting of (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxy-ethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo-[1,2-h][1,7]naphthyridine (Soraprazan) or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof, and wherein the airway therapeutic is CICLESONIDE or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.

5. A pharmaceutical preparation comprising as active compounds, a reversible proton pump inhibitor and an airway therapeutic.

25. A pharmaceutical preparation according to claim 5, wherein the reversible proton pump inhibitor is selected from the group consisting of AU-461, BY359, DBM-819, KR-60436, T-330, YH-1885, YJA-20379-8 and (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine and the hydrates, solvates, salts, hydrates of the salts and solvates of the salts thereof.

26. A pharmaceutical preparation according to claim 5, wherein the airway therapeutic is selected from the group consisting of cis-[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexane-1-carboxylic acid (CILOMILAST), 2-methyl-1-[2-(1-methylethyl)pyrazolo-[1,5-a]pyridin-3-yl]-1-propanone (IBUDILAST), (−

)-cis-9-ethoxy-8-methoxy-2-methyl-1,2,3,4,4a,10b-hexahydro-6-(4-diisopropylamino-carbonylphenyl)benzo[c][1,6]-naphthyridine (PUMAFENTRINE), 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridyl)-4-difluoromethoxy)benzamide (ROFLUMILAST), ROFLUMILAST N-OXIDE and the hydrates, solvates, salts, hydrates of the salts and solvates of the salts thereof.

27. A pharmaceutical preparation according to claim 5, wherein the reversible proton pump inhibitor is selected from the group consisting of (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo-[1,2-h][1,7]naphthyridine (Soraprazan), (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7H-8,9-dihydro-pyrano[2,3-c]imidazo[1,2-a]pyridine, (7R,8R,9R)-7-(2-methoxyethoxy)-2,3-dimethyl-8-(N,N-dimethylaminomethylcarbonyloxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine, 7-(4-fluoro-benzyloxy)-2,3-dimethyl-1-(2-methyl-cyclopropylmethyl)-1H-pyrrolo[2,3-d]pyridazine, 7-(4-chloro-benzyloxy)-2,3-dimethyl-1-(2-methyl-cyclopropylmethyl)-1H-pyrrolo[2,3-d]pyridazine, 7-(2,4-difluoro-benzyloxy)-2,3-dimethyl-1-(2-methyl-cyclopropylmethyl)-1H-pyrrolo[2,3-d]pyridazine, 8-(2,6-dimethyl-benzylamino)-2,3-dimethyl-imidazo[1,2-a]pyridine-6-carboxylic acid (2-hydroxy-ethyl)-amide, 8-(2-ethyl-6-methyl-benzylamino)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxylic acid amide and the hydrates, solvates, salts, hydrates of the salts and solvates of the salts thereof.

28. A pharmaceutical preparation according to claim 5, wherein the reversible proton pump inhibitor is selected from the group consisting of (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxy-ethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo-[1,2-h][1,7]naphthyridine (Soraprazan), (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7H-8,9-dihydro-pyrano[2,3-c]imidazo[1,2-a]pyridine, (7R,8R,9R)-7-(2-methoxyethoxy)-2,3-dimethyl-8-(N,N-dimethylaminomethylcarbonyloxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine and the hydrates, solvates, salts, hydrates of the salts and solvates of the salts thereof.

29. A pharmaceutical preparation according to claim 5, wherein the reversible proton pump inhibitor is selected from the group consisting of (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxy-ethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo-[1,2-h][1,7]naphthyridine (Soraprazan), (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7H-8,9-dihydro-pyrano[2,3-c]imidazo[1,2-a]pyridine, (7R,8R,9R)-7-(2-methoxyethoxy)-2,3-dimethyl-8-(N,N-dimethylaminomethylcarbonyloxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine and the hydrates, solvates, salts, hydrates of the salts and solvates of the salts thereof, and wherein the airway therapeutic is CICLESONIDE or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.

30. A pharmaceutical preparation according to claim 5, wherein the reversible proton pump inhibitor is selected from the group consisting of (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxy-ethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo-[1,2-h][1,7]naphthyridine (Soraprazan), (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7H-8,9-dihydro-pyrano[2,3-c]imidazo[1,2-a]pyridine, (7R,8R,9R)-7-(2-methoxyethoxy)-2,3-dimethyl-8-(N,N-dimethylaminomethylcarbonyloxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine and the hydrates, solvates, salts, hydrates of the salts and solvates of the salts thereof, and wherein the airway therapeutic is 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridyl)-4-(difluoromethoxy)benzamide (ROFLUMILAST), ROFLUMILAST-N-OXIDE or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.

31. A pharmaceutical preparation according to claim 5, wherein the reversible proton pump inhibitor is selected from the group consisting of (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxy-ethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo-[1,2-h][1,7]naphthyridine (Soraprazan) or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof, and wherein the airway therapeutic is 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridyl)-4-(difluoromethoxy)benzamide (ROFLUMILAST) or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.

32. A pharmaceutical preparation according to claim 5, wherein the reversible proton pump inhibitor is selected from the group consisting of (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxy-ethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo-[1,2-h][1,7]naphthyridine (Soraprazan) or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof, and wherein the airway therapeutic is CICLESONIDE or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.

6. A ready-to-use medicament, comprising, as active compounds, a reversible proton pump inhibitor and an airway therapeutic, which contains a reference to the fact that said active compounds are to be taken for the treatment of an airway disorder more or less simultaneously or in succession.

33. A ready-to-use medicament according to claim 6, wherein the reversible proton pump inhibitor is selected from the group consisting of AU-461, BY359, DBM-819, KR-60436, T-330, YH-1885, YJA-20379-8 and (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine and the hydrates, solvates, salts, hydrates of the salts and solvates of the salts thereof.

34. A ready-to-use medicament according to claim 6, wherein the airway therapeutic is selected from the group consisting of cis-[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexane-1-carboxylic acid (CILOMILAST), 2-methyl-1-[2-(1-methylethyl)pyrazolo-[1,5-a]pyridin-3-yl]-1-propanone (IBUDILAST), (−

)-cis-9-ethoxy-8-methoxy-2-methyl-1,2,3,4,4a,10b-hexahydro-6-(4-diisopropylamino-carbonylphenyl)benzo[c][1,6]-naphthyridine (PUMAFENTRINE), 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridyl)-4-difluoromethoxy)benzamide (ROFLUMILAST), ROFLUMILAST N-OXIDE and the hydrates, solvates, salts, hydrates of the salts and solvates of the salts thereof.

35. A ready-to-use medicament according to claim 6, wherein the reversible proton pump inhibitor is selected from the group consisting of (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo-[1,2-h][1,7]naphthyridine (Soraprazan), (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7H-8,9-dihydro-pyrano[2,3-c]imidazo[1,2-a]pyridine, (7R,8R,9R)-7-(2-methoxyethoxy)-2,3-dimethyl-8-(N,N-dimethylaminomethylcarbonyloxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine, 7-(4-fluoro-benzyloxy)-2,3-dimethyl-1-(2-methyl-cyclopropylmethyl)-1H-pyrrolo[2,3-d]pyridazine, 7-(4-chloro-benzyloxy)-2,3-dimethyl-1-(2-methyl-cyclopropylmethyl)-1H-pyrrolo[2,3-d]pyridazine, 7-(2,4-difluoro-benzyloxy)-2,3-dimethyl-1-(2-methyl-cyclopropylmethyl)-1H-pyrrolo[2,3-d]pyridazine, 8-(2,6-dimethyl-benzylamino)-2,3-dimethyl-imidazo[1,2-a]pyridine-6-carboxylic acid (2-hydroxy-ethyl)-amide, 8-(2-ethyl-6-methyl-benzylamino)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxylic acid amide and the hydrates, solvates, salts, hydrates of the salts and solvates of the salts thereof.

36. A ready-to-use medicament according to claim 6, wherein the reversible proton pump inhibitor is selected from the group consisting of (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxy-ethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo-[1,2-h][1,7]naphthyridine (Soraprazan), (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7H-8,9-dihydro-pyrano[2,3-c]imidazo[1,2-a]pyridine, (7R,8R,9R)-7-(2-methoxyethoxy)-2,3-dimethyl-8-(N,N-dimethylaminomethylcarbonyloxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine and the hydrates, solvates, salts, hydrates of the salts and solvates of the salts thereof.

37. A ready-to-use medicament according to claim 6, wherein the reversible proton pump inhibitor is selected from the group consisting of (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxy-ethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo-[1,2-h][1,7]naphthyridine (Soraprazan), (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7H-8,9-dihydro-pyrano[2,3-c]imidazo[1,2-a]pyridine, (7R,8R,9R)-7-(2-methoxyethoxy)-2,3-dimethyl-8-(N,N-dimethylaminomethylcarbonyloxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine and the hydrates, solvates, salts, hydrates of the salts and solvates of the salts thereof, and wherein the airway therapeutic is CICLESONIDE or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.

38. A ready-to-use medicament according to claim 6, wherein the reversible proton pump inhibitor is selected from the group consisting of (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxy-ethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo-[1,2-h][1,7]naphthyridine (Soraprazan), (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7H-8,9-dihydro-pyrano[2,3-c]imidazo[1,2-a]pyridine, (7R,8R,9R)-7-(2-methoxyethoxy)-2,3-dimethyl-8-(N,N-dimethylaminomethylcarbonyloxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine and the hydrates, solvates, salts, hydrates of the salts and solvates of the salts thereof, and wherein the airway therapeutic is 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridyl)-4-(difluoromethoxy)benzamide (ROFLUMILAST), ROFLUMILAST-N-OXIDE or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.

39. A ready-to-use medicament according to claim 6, wherein the reversible proton pump inhibitor is selected from the group consisting of (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxy-ethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo-[1,2-h][1,7]naphthyridine (Soraprazan) or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof, and wherein the airway therapeutic is 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridyl)-4-(difluoromethoxy)benzamide (ROFLUMILAST) or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.

40. A ready-to-use medicament according to claim 6, wherein the reversible proton pump inhibitor is selected from the group consisting of (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxy-ethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo-[1,2-h][1,7]naphthyridine (Soraprazan) or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof, and wherein the airway therapeutic is CICLESONIDE or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.

7. A ready-to-use medicament, comprising, as active compound, a reversible proton pump inhibitor, which contains a reference to the fact that said reversible proton pump inhibitor is to be taken for the treatment of an airway disorder more or less simultaneously or in succession with an airway therapeutic.

41. A ready-to-use medicament according to claim 7, wherein the reversible proton pump inhibitor is selected from the group consisting of AU-461, BY359, DBM-819, KR-60436, T-330, YH-1885, YJA-20379-8 and (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine and the hydrates, solvates, salts, hydrates of the salts and solvates of the salts thereof.

42. A ready-to-use medicament according to claim 7, wherein the airway therapeutic is selected from the group consisting of cis-[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexane-1-carboxylic acid (CILOMILAST), 2-methyl-1-[2-(1-methylethyl)pyrazolo-[1,5-a]pyridin-3-yl]-1-propanone (IBUDILAST), (−

)-cis-9-ethoxy-8-methoxy-2-methyl-1,2,3,4,4a,10b-hexahydro-6-(4-diisopropylamino-carbonylphenyl)benzo[c][1,6]-naphthyridine (PUMAFENTRINE), 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridyl)-4-difluoromethoxy)benzamide (ROFLUMILAST), ROFLUMILAST N-OXIDE and the hydrates, solvates, salts, hydrates of the salts and solvates of the salts thereof.

43. A ready-to-use medicament according to claim 7, wherein the reversible proton pump inhibitor is selected from the group consisting of (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo-[1,2-h][1,7]naphthyridine (Soraprazan), (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7H-8,9-dihydro-pyrano[2,3-c]imidazo[1,2-a]pyridine, (7R,8R,9R)-7-(2-methoxyethoxy)-2,3-dimethyl-8-(N,N-dimethylaminomethylcarbonyloxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine, 7-(4-fluoro-benzyloxy)-2,3-dimethyl-1-(2-methyl-cyclopropylmethyl)-1H-pyrrolo[2,3-d]pyridazine, 7-(4-chloro-benzyloxy)-2,3-dimethyl-1-(2-methyl-cyclopropylmethyl)-1H-pyrrolo[2,3-d]pyridazine, 7-(2,4-difluoro-benzyloxy)-2,3-dimethyl-1-(2-methyl-cyclopropylmethyl)-1H-pyrrolo[2,3-d]pyridazine, 8-(2,6-dimethyl-benzylamino)-2,3-dimethyl-imidazo[1,2-a]pyridine-6-carboxylic acid (2-hydroxy-ethyl)-amide, 8-(2-ethyl-6-methyl-benzylamino)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxylic acid amide and the hydrates, solvates, salts, hydrates of the salts and solvates of the salts thereof.

44. A ready-to-use medicament according to claim 7, wherein the reversible proton pump inhibitor is selected from the group consisting of (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxy-ethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo-[1,2-h][1,7]naphthyridine (Soraprazan), (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7H-8,9-dihydro-pyrano[2,3-c]imidazo[1,2-a]pyridine, (7R,8R,9R)-7-(2-methoxyethoxy)-2,3-dimethyl-8-(N,N-dimethylaminomethylcarbonyloxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine and the hydrates, solvates, salts, hydrates of the salts and solvates of the salts thereof.

45. A ready-to-use medicament according to claim 7, wherein the reversible proton pump inhibitor is selected from the group consisting of (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxy-ethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo-[1,2-h][1,7]naphthyridine (Soraprazan), (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7H-8,9-dihydro-pyrano[2,3-c)imidazo[1,2-a]pyridine, (7R,8R,9R)-7-(2-methoxyethoxy)-2,3-dimethyl-8-(N,N-dimethylaminomethylcarbonyloxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine and the hydrates, solvates, salts, hydrates of the salts and solvates of the salts thereof, and wherein the airway therapeutic is CICLESONIDE or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.

46. A ready-to-use medicament according to claim 7, wherein the reversible proton pump inhibitor is selected from the group consisting of (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxy-ethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo-[1,2-h][1,7]naphthyridine (Soraprazan), (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7H-8,9-dihydro-pyrano[2,3-c]imidazo[1,2-a]pyridine, (7R,8R,9R)-7-(2-methoxyethoxy)-2,3-dimethyl-8-(N,N-dimethylaminomethylcarbonyloxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine and the hydrates, solvates, salts, hydrates of the salts and solvates of the salts thereof and wherein the airway therapeutic is 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridyl)-4-(difluoromethoxy)benzamide (ROFLUMILAST), ROFLUMILAST-N-OXIDE or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.

47. A ready-to-use medicament according to claim 7, wherein the reversible proton pump inhibitor is selected from the group consisting of (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxy-ethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo-[1,2-h][1,7]naphthyridine (Soraprazan) or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof, and wherein the airway therapeutic is 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridyl)-4-(difluoromethoxy)benzamide (ROFLUMILAST) or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.

48. A ready-to-use medicament according to claim 7, wherein the reversible proton pump inhibitor is selected from the group consisting of (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxy-ethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo-[1,2-h][1,7]naphthyridine (Soraprazan) or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof, and wherein the airway therapeutic is CICLESONIDE or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.

8. A ready-to-use medicament, comprising, as active compound, an airway therapeutic, which contains a reference to the fact that said airway therapeutic is to be taken for the treatment of an airway disorder more or less simultaneously or in succession with a reversible proton pump inhibitor.

49. A ready-to-use medicament according to claim 8, wherein the reversible proton pump inhibitor is selected from the group consisting of AU-461, BY359, DBM-819, KR-60436, T-330, YH-1885, YJA-20379-8 and (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine and the hydrates, solvates, salts, hydrates of the salts and solvates of the salts thereof.

50. A ready-to-use medicament according to claim 8, wherein the airway therapeutic is selected from the group consisting of cis-[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexane-1-carboxylic acid (CILOMILAST), 2-methyl-1-[2-(1-methylethyl)pyrazolo-[1,5-a]pyridin-3-yl]-1-propanone (IBUDILAST), (−

)-cis-9-ethoxy-8-methoxy-2-methyl-1,2,3,4,4a,10b-hexahydro-6-(4-diisopropylamino-carbonylphenyl)benzo[c][1,6]-naphthyridine (PUMAFENTRINE), 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridyl)-4-difluoromethoxy)benzamide (ROFLUMILAST), ROFLUMILAST N-OXIDE and the hydrates, solvates, salts, hydrates of the salts and solvates of the salts thereof.

51. A ready-to-use medicament according to claim 8, wherein the reversible proton pump inhibitor is selected from the group consisting of (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo-[1,2-h][1,7]naphthyridine (Soraprazan), (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7H-8,9-dihydro-pyrano[2,3-c]imidazo[1,2-a]pyridine, (7R,8R,9R)-7-(2-methoxyethoxy)-2,3-dimethyl-8-(N,N-dimethylaminomethylcarbonyloxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine, 7-(4-fluoro-benzyloxy)-2,3-dimethyl-1-(2-methyl-cyclopropylmethyl)-1H-pyrrolo[2,3-d]pyridazine, 7-(4-chloro-benzyloxy)-2,3-dimethyl-1-(2-methyl-cyclopropylmethyl)-1H-pyrrolo[2,3-d]pyridazine, 7-(2,4-difluoro-benzyloxy)-2,3-dimethyl-1-(2-methyl-cyclopropylmethyl)-1H-pyrrolo[2,3-d]pyridazine, 8-(2,6-dimethyl-benzylamino)-2,3-dimethyl-imidazo[1,2-a]pyridine-6-carboxylic acid (2-hydroxy-ethyl)-amide, 8-(2-ethyl-6-methyl-benzylamino)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxylic acid amide and the hydrates, solvates, salts, hydrates of the salts and solvates of the salts thereof.

52. A ready-to-use medicament according to claim 8, wherein the reversible proton pump inhibitor is selected from the group consisting of (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxy-ethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo-[1,2-h][1,7]naphthyridine (Soraprazan), (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7H-8,9-dihydro-pyrano[2,3-c]imidazo[1,2-a]pyridine, (7R,8R,9R)-7-(2-methoxyethoxy)-2,3-dimethyl-8-(N,N-dimethylaminomethylcarbonyloxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine and the hydrates, solvates, salts, hydrates of the salts and solvates of the salts thereof.

53. A ready-to-use medicament according to claim 8, wherein the reversible proton pump inhibitor is selected from the group consisting of (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxy-ethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo-[1,2-h][1,7]naphthyridine (Soraprazan), (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7H-8,9-dihydro-pyrano[2,3-c]imidazo[1,2-a]pyridine, (7R,8R,9R)-7-(2-methoxyethoxy)-2,3-dimethyl-8-(N,N-dimethylaminomethylcarbonyloxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine and the hydrates, solvates, salts, hydrates of the salts and solvates of the salts thereof, and wherein the airway therapeutic is CICLESONIDE or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.

54. A ready-to-use medicament according to claim 8, wherein the reversible proton pump inhibitor is selected from the group consisting of (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxy-ethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo-[1,2-h][1,7]naphthyridine (Soraprazan), (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7H-8,9-dihydro-pyrano[2,3-c]imidazo[1,2-a]pyridine, (7R,8R,9R)-7-(2-methoxyethoxy)-2,3-dimethyl-8-(N,N-dimethylaminomethylcarbonyloxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine and the hydrates, solvates, salts, hydrates of the salts and solvates of the salts thereof, and wherein the airway therapeutic is 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridyl)-4-(difluoromethoxy)benzamide (ROFLUMILAST), ROFLUMILAST-N-OXIDE or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.

55. A ready-to-use medicament according to claim 8, wherein the reversible proton pump inhibitor is selected from the group consisting of (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxy-ethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo-[1,2-h][1,7]naphthyridine (Soraprazan) or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof, and wherein the airway therapeutic is 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridyl)-4-(difluoromethoxy)benzamide (ROFLUMILAST) or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.

56. A ready-to-use medicament according to claim 8, wherein the reversible proton pump inhibitor is selected from the group consisting of (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxy-ethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo-[1,2-h][1,7]naphthyridine (Soraprazan) or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof, and wherein the airway therapeutic is CICLESONIDE or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.